Chinese pharmaceutical company Sinopharm has offered Pakistan’s National Institute of Health for clinical trials of COVID-19 vaccine.
“We would like to extend our offer for cooperation on conducting clinical trials of our recently developed inactivated COVID-19 vaccine to the National Institute of Health (NIH) in our brotherly country, Pakistan,” read the letter sent to Major General Prof Dr. Aamir Ikram, Executive Director of National Institute of Health, by the general manager of China Sinopharm International Corp., Li Can.
“We hope that a successful clinical trial in Pakistan will make it one of the first few countries for the launch of a Covid-19 vaccine,” added the letter.
The Chinese firm said that it is one of the first organizations to have led the development of a vaccine for the novel coronavirus. A state-owned enterprise, Sinopharm produces more than 80 percent of the mandatory immunization needs of China and played a leading role in fighting the COVID-19 crisis in the country.